You're Watching:

2010 JP Morgan Healthcare Conference, the Insider Perspective - Part 2

At the end of the 2010 JPM conf, what is the best company-profile for a successful IPO? Is it true that Pharma's validation is no longer sought? Is there a new trend in business models for biotech? What is the take home message of the 2010 conference? An interview of Geoff Meacham of JP Morgan, by Marina Bozilenko.

This interview was conducted at the JP Morgan Conference, on January 13th, 2010, in San Francisco.

Featuring:

• Geoff Meacham, Senior Biotechnology Analyst, JP Morgan
• Marina Bozilenko, Executive Producer, BioBusiness.TV

DISCLAIMER: VIEWERS SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.

Login or register to write a review